Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending oral doses of AZD1656 in Japanese patients with type 2 diabetes mellitus
jRCT2080220768Phase 1
- Sponsor
- AstraZeneca
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing AZD1656 with Placebo (2 arms). Primary endpoints: Safety and tolerability of multiple ascending doses of AZD1656, Pharmacokinetics of AZD1656 and 1 more.
02
Drugs
AZD1656
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080220768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220768.